Yearend

Active Biotech Year End Report 2023

FOURTH QUARTER IN BRIEF Lead Principal Investigator Rebekka Schneider-Kramann presents the clinical plan and positioning of tasquinimod in myelofibrosis (December 1) Active Biotech enters into collaboration agreement for clinical ocular biodistribution study with laquinimod (December 5) Active Biotech announces outcome of the Company’s rights issue (December 6) Preclinical data of…

Active Biotech Year End Report 2022

FOURTH QUARTER IN BRIEF Active Biotech further strengthened the patent protection for laquinimod in eye disorders with a granted patent in US (Oct 24) Preclinical data with tasquinimod in MDS presented at ASH 2022 (Dec 13) Phase I Multiple dose study of laquinimod recruited final patient OTHER SIGNIFICANT EVENTS JAN…

Correction: Active Biotech Year End Report 2021

The correction refers to the administrative costs for the period January – December 2021 that due to oversight have been stated too low. The incorrect amount was SEK 14,0 M, the correct amount is SEK 15,2 M. The error has been discovered in connection with the finalization of the Annual…

Active Biotech Year-end report January – December 2020

       New strategic R&D plan implemented and financed Fourth quarter in briefTasquinimod The clinical study in multiple myeloma was presented at an oral poster session at the virtual American Society of Hematology (ASH) 2020 meeting in December Patent granted in China in October regarding treatment of multiple myeloma…

Active Biotech AB – Year-end report January – December 2019

                                                                                                   …

Active Biotech Year-end report January – December 2018

Fourth quarter in brief Active Biotech communicated updated information about its financial position New data from the LEGATO-HD study presented at the 2018 HSG conference Other significant events during the January-December period Patent regarding tasquinimod for the treatment of multiple myeloma (MM) granted in the US The rights issue in…

Active Biotech AB Year-end report January – December 2017

Fourth quarter in brief The primary clinical endpoint was not met in the Phase II study (ARPEGGIO) with laquinimod in PPMS Patent regarding tasquinimod for the treatment of acute leukemia granted in Europe The process to divest the company’s property in Lund is ongoing On December 7, the company announced…

Active Biotech AB Year-end report January – December 2016

Laquinimod The clinical trials CONCERTO, ARPEGGIO and LEGATO-HD are progressing according to plan The study results from the pivotal clinical Phase 3 CONCERTO trial in relapsing remitting multiple sclerosis (RRMS) are expected in the first half of 2017 The study results from the clinical Phase 2 ARPEGGIO trial, evaluating laquinimod…

Active Biotech AB Year-end report January – December 2015

Laquinimod· In April, it was announced that the first patient was enrolled to ARPEGGIO, which is evaluating laquinimod’s potential for treatment of primary progressive multiple sclerosis (PPMS)· In June, it was announced that the company was to focus its operations on the laquinimod projects and adjust the organization accordingly· In June, it was…

Active Biotech AB Year-end report January – December 2014

Laquinimod · The pivotal CONCERTO clinical study is continuing according to plan and results are expected in 2016. · In May 2014, EMA’s Committee for Medicinal Products for Human Use (CHMP) announced that the risks observed in animal studies did not prevent registration for treatment in humans. CHMP confirmed its January 2014…

Active Biotech AB Year-end report January – December 2013

Laquinimod Teva remains committed to the development of laquinimod (NERVENTRA®) for the treatment of multiple sclerosis (MS) On January 24, laquinimod received a negative opinion by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). The CHMP’s opinion was based on the view that…

Active Biotech AB Year-end report January – December 2012

Events for the full year 2012 Laquinimod Phase III data presented at the AAN (64th Annual Meeting of the American Academy of Neurology) Application submitted for regulatory approval in the EU, milestone payment of USD 5 M from Teva Teva initiates a Phase III study in multiple sclerosis (the CONCERTO…

Year-end Report January – December 2011

· Laquinimod – a clinical trial is planned prior to filing an NDA in the US                      · TASQ         – an investigator-sponsored Phase I clinical trial launched                     – enrolment of patients for Phase III trial proceeding according to plan   · ANYARA    – Phase III trial continuing according to plan · 57-57          – a clinical trial in…

Active Biotech AB Year-end Report January – December 2010

· Laquinimod – positive results presented from ALLEGRO Phase III trial · TASQ – pivotal Phase III study initiated in the first quarter of 2011 · ANYARA – ongoing Phase III study expected to be concluded in 2012 · 57-57 – recommended Orphan Medicinal Product Status · ISI – project proceeding according to plan · RhuDex(TM) – preparations for continued clinical development…